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Abstract 
Aberrant signaling by the epidermal growth factor receptor (ErbB) family plays a central 
role in tumor development and is a target for pharmacological intervention. A major 
challenge in drug discovery is the evaluation of new compounds at the organismal level. 
Due to conservation of the ErbB network between Drosophila and humans, flies offer an 
attractive system for this. I have generated transgenic Drosophila with human ErbB 
receptors and used them to develop an in vivo assay to screen for therapeutics. 
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Introduction  
Cancer is currently the second leading cause of death in the western world and its global 
health burden continues to increase at an alarming pace. One in every eight deaths 
worldwide is caused by cancer – more than AIDS, malaria and tuberculosis combined. It is 
estimated that in 2008 alone, there were 7.4 million deaths from cancer and 12.4 million 
new diagnosed cases around the world (American Cancer Society, 2010). Advances in 
diagnosis and treatment have increased patient survival in several types of solid tumors. 
However, drug resistance and treatment-related toxicity still remain a major cause for the 
overall poor patient outcome associated with cancer.  Consequently, there is an increasing 
need to develop more effective treatments to improve patient survival (Madhusudan & 
Ganesan, 2004).  
Advances in our understanding of the biology of cancer have led to the identification of 
receptor tyrosine kinases (RTK), a class of transmembrane receptors, coupled to complex 
signal transduction networks that regulate critical cellular processes such as survival, 
proliferation, differentiation and migration. Aberrant signaling by RTKs is the hallmark of 
human oncogenesis and has emerged as a major mechanism for tumor cell proliferation 
and survival. Consequently, RTKs have provided a new arena for oncology drug discovery, 
where a novel class of therapeutic compounds is developed to specifically block or 
attenuate RTK activity (Lemmon & Schlessinger, 2010).  
The Epidermal Growth Factor Receptor Family of RTKs 
The epidermal growth factor receptor family is a subclass of RTKs and comprises four 
members: ErbB1/EGFR, ErbB2/HER2, ErbB3/HER3 and ErbB4/HER4. ErbB1 was the first 
RTK to be discovered and subsequently provided the first relationship between an 
oncogene and cancer. Upon ligand binding, the receptors form homo and heterodimeric 
complexes to initiate intricate signal transduction cascades that relay information to the 
nucleus and control a diverse array of cellular processes including differentiation, 
proliferation, apoptosis and migration(Bazley & Gullick, 2005).  
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The ErbB receptors  and their pivotal role in cell fate determination appear to be 
evolutionary conserved. Drosophila melanogaster has an ErbB homolog named DER, which 
shares many structural and functional similarities with the human receptors. The overall 
amino acid identity between ErbB1 and DER is 38% (Bogdan & Klambt, 2001). EGFR 
signaling in vertebrates is essential for normal development as demonstrated by studies in 
genetically modified mice. Loss of EGFR signaling causes embryonic or perinatal lethality in 
mice and abnormalities in multiple organs including brain, skin, lung heart and 
gastrointestinal tract. In addition, the EGFR receptors promote mammary gland 
development in the adult (Olayioye, et al., 2000).  
Domain Architecture of the ErbB Family 
The four members of the EGFR family are closely related transmembrane glycoproteins 
that contain three functional regions: an extracellular region for ligand binding and 
receptor dimerization, a single transmembrane domain and a cytoplasmic region (Fig. 1) 
(Bazley & Gullick, 2005). 
 
 
Figure 1: Structure of the Drosophila and Human Epidermal Growth Factor Receptors 
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The extracellular region of the four ErbB receptors consist of two homologous large 
domains (I and III) and two cysteine-rich domains (II and IV). Domains I and III are 
important for ligand binding, while receptor dimerization is mediated principally by 
domain II. In addition, structural studies have identified a small region within domain IV 
that is also involved in physical receptor-receptor interactions (Fig. 1) (Burgess et al., 
2003).   
The cytoplasmic region of the EGFR receptors contains three distinct domains: the 
juxtamembrane domain that interacts with protein kinase C (PKC), the non-catalytic 
carboxy-terminal tail housing the tyrosine transphosphorylation sites and the tyrosine 
kinase domain, which transphosphorylates carboxy-terminal tyrosine residues (Blazley et 
al). 
Ligand Binding and Receptor Activation 
The ErbB receptors are activated by members of the EGF family of peptide growth factors 
which include EGF, transforming growth factor-alpha (TGF-α), amphiregulin (AR), 
betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), epiregulin (EPR), 
epigen (EPG), and the neuroglins (Fig. 2) (Wilson et al., 2009). 
 
Figure 2: EGF ligand family bind and activate multiple EGFR receptors. 
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In the absence of ligands the ErbB receptors exist as inactive tethered monomers due to 
direct intramolecular interactions between domains II and IV. By binding simultaneously to 
both domains I and III, the ligand induces substantial conformational rearrangements of 
the extracellular region, exposing a dimerization arm in domain II (Fig. 3). These 
conformational changes promote receptor homo- and heterodimerization and subsequent 
activation of the intracellular kinase domain. Each receptor in the dimer 
transphosphorylates specific tyrosine residues on the C-terminal domain of its partner. The 
resulting phosphotyrosines then become docking sites for various signaling molecules 
initiating a diverse array of downstream signaling pathways (Burgess et al., 2003). 
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Fig. 3: Ligand-Induced Receptor Dimerization 
Two of the ErbB receptors possess unique characteristics that distinguish them from the 
rest of the ErbB family members. ErbB3 has a defective intracellular kinase domain and is 
incapable of phosphorylating the C-terminal tyrosine residues of its dimerization partners. 
The second member of the family, ErbB2, has no known ligand that interacts with its 
extracellular domains. Nevertheless, ErbB2 is capable of initiating potent signaling 
cascades upon dimerization and is the only receptor in the family that can transform cells 
when simply overexpressed (Burgess et al., 2003). Structural studies revealed that 
unliganded ErbB2 lacks the autoinhibitory domain II/IV tether interactions and adopts a 
constitutively extended extracellular configuration with its dimerization arm exposed.  This 
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extracellular domain arrangement resembles the active conformation of the rest of the 
ErbB family members and, strikingly, the unliganded conformation of the Drosophila ErbB 
homolog, DER (Alvarado et al., 2009).  
Unlike the orphan ErbB2, four ligands (Spitz, Gurken, Keren and Vein) tightly regulate DER 
and are required for receptor activation and dimerization. This suggests that 
autoinhibitory interactions, different from those present in ErbB1, ErbB3 and ErbB4, keep 
unliganded DER in an inactive conformation. Although the dimerization arm of DER is 
exposed in the absence of a ligand, direct interactions between domains I and III keep the 
dimerization arm in an orientation that inhibits receptor dimerization. Ligand binding 
pushes domains I and III apart from each other causing domain II to bend and reorient its 
dimerization arm. The resulting rearrangements are necessary for receptor-receptor 
interactions. The structural similarities between the inactive DER and ErbB2 together with 
fact that ErbB2 has more propensity to form heterodimers than homodimers, suggest that 
ErbB2 possibly utilizes a similar autoinhibitory mechanism (Alvarado et al., 2009).  
Downstream Signaling Pathways 
Activated receptor dimers often utilize the mitogen activated protein kinase (MAPK) 
pathways to relay information to the nucleus. The MAPK pathway is a highly conserved 
signaling module that regulates fundamental cellular processes such as proliferation, 
differentiation and survival. Mammalian cells utilize four MAPK pathways that consist of 
three enzymes: MAPK kinase kinase (MAP3K), MAPK kinase (MAP2K) and MAPK. Among 
the four MAPK pathways, the RAF-MEK-ERK signaling pathway is the most extensively 
studied, reflecting its established role in tumor development (Fig. 4). Aberrant activation of 
the cascade can occur through either a ligand-induced signaling by receptor tyrosine 
kinases or mutations and overexpression of the proteins that constitute the pathway 
(Montagut & Settleman, 2009).  
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Fig. 4: ErbB Mediated Activation of the MAPK Pathway. 
 
 
Receptor dimerization and subsequent phosphorylation of specific tyrosine residues at the 
C-terminal tail create docking sites for various second messenger molecules that link 
activated receptors to distinct downstream signaling cascades. These second messenger 
molecules can be either adaptor proteins or enzymes that bind to phosphotyrosine 
residues via SH2 (src homology) or PTB (phosphotyrosine binding) domains (Prenze et al., 
2001). Two adaptor proteins, Shc (src-homology 2 containing) and Grb2 (growth factor 
receptor bound-2) provide a link between the active ErbB1 receptor and the MAPK 
signaling pathway (Fig. 4). Shc binds directly to phosphotyrosine residues of the active 
receptor and recruits Grb2 which in turn associates with the guanine nucleotide exchange 
factor SOS (son-of-sevenless). SOS activates the small G-protein Ras by exchanging GDP for 
GTP. Ras then undergoes a conformational change that allows it to interact with the 
serine/threonine kinase Raf. This results in Raf translocation to the cell membrane where 
its activation takes place. Raf then activates the tyrosine and serine/threonine dual 
specificity kinase MEK by phosphorylating S residues in its catalytic domain. MEK in turn 
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phosphorylates and activates the serine/threonine kinases ERK1/2 (extracellular-signal- 
activated-kinases, also known as MAPK) which can translocate to the nucleus and directly 
activate transcriptional factors including Ets-1, c-Jun and c-Myc (McCubrey et al., 2006).  
Regulation of Receptor Signaling 
Following ligand binding and subsequent receptor activation, the ErbB dimers are targeted 
for endocytosis in clathrin-coated membrane invaginations, which pinch off to form 
vesicles that deliver the receptors to endosomes. Internalized receptors are either targeted 
for lysosomal degradation or recycled back to the plasma membrane. This mechanism 
regulates the mitogenic potency of the ErbB receptors through modulating signal strength 
and duration early in the signaling pathway (Sorkin & Goh, 2009).  
Translocation of active receptor dimers to endosomes is followed by recruitment of the E3 
ubiquitin ligase Cbl, which associates with specific phosphotyrosines at the C-terminal tail 
of the receptors. The mammalian family of Cbl proteins comprises three members, c-Cbl, 
Cbl-b and Cbl-3, which directly bind specific ErbB phosphotyrosines via their tyrosine 
kinase binding (TKB) domains. In addition, the Cbl proteins contain a RING Finger domain 
that recruits E2 ubiquitin conjugating enzymes. Thus, Cbl targets internalized receptors for 
lysosomal degradation by promoting receptor ubiqiutination (Sorkin & Goh, 2009).  
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Figure 5: Ligand-induced receptor endocytosis. 
 
Another determinant of receptor fate following endocytosis is the stability of the activated 
receptor-ligand complex. In the slightly acidic endosomal environment receptor 
homodimers remain stably bound to their ligands, which promotes receptor ubiquitination 
by Cbl and subsequent lysosomal degradation. By contrast, the ErbB heterodimers are less 
stable in the acidic endosomal environment causing the ligand and Cbl to dissociate. As a 
result, the receptors are recycled back to the cell membrane (Fig. 5). This differential 
endocytinc routing of receptor dimers partially accounts for the enhanced mitogenic 
potency of heterodimers (Lenferink et al., 1998). 
Epidermal Growth Factor Receptors in Cancer 
In normal cells, the potent mitogenic signals generated by the ErbB receptors are tightly 
regulated through mechanisms such as receptor endocytosis to ensure proper 
interpretation of the extracellular signals. On the other hand, dysregulation of the ErbB 
signaling pathways contributes to uncontrolled cell proliferation and has been implicated 
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in the development and progression of multiple types of cancer including breast, lung, 
brain and head and neck cancer (Table 1). Hyperactivation of the ErbB network in cancer is 
usually the result of the following three mechanisms: overexpression of receptors as a 
result of gene amplification or polysomy, overproduction of receptor ligands, or somatic 
mutations that lead to the production of receptors that are constitutively active even in the 
absence of a ligand (Yarden & Sliwkowski, 2001).  
Table 1: ErbBs expression in cancer (Yarden & Sliwkowski, 2001) 
Receptor Type of Dysregulation Type of Cancer 
ErbB1 Overexpression Head and neck, breast, 
bladder, prostate, kidney, 
lung, glioma 
 Mutation Breast, glioma, lung, ovary 
ErbB2 Overexpresion Breast, lung, pancreas, colon, 
oesophagus, endometrium, 
cervix 
ErbB3 Expression Breast, colon, gastric, 
prostate 
 Overexpression Oral squamous cell cancer 
ErbB4 Expression Childhood meduloblastoma 
 
Overexpression and structural changes in the ErbB receptors are both implicated in the 
development of human malignancies. However, in vitro studies demonstrate that 
overproduction of normal receptors causes cell transformation only in the presence of 
appropriate levels of ligands. For instance, overexpression of ErbB1 in mouse NIH-3T3 cells 
leads to transformation of these cells only upon addition of EGF, which is necessary for 
receptor activation. Increased levels of ErbB1 expression occur in 40% of human gliomas 
and are associated with poor patient outcome. In addition, a specific type of ErbB1 
mutation that results in constitutively active receptor due to deletions in the extracellular 
domains has been identified in ovary and breast carcinomas (Normanno et al., 2006).  
 
Deregulated signaling by the ErbB1 receptor has also been associated with the formation 
and pathogenesis of non-small cell lung carcinoma (NSCLC), which is characterized by a 
particularly adverse clinical prognosis. NSCLC is the leading cause of cancer death 
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worldwide accounting for one third of all cancer deaths. The disease is characterized by a 
high metastatic rate and a median patient survival of only 4-5 months after diagnosis. 
Overexpression of ErbB1 has been observed in 62% of NSCLC and contributes to a poor 
patient outcome. ErbB1 mutations are present in approximately 10% of the NSCLC cases in 
North America and Western Europe and are usually found in exons encoding the tyrosine 
kinase domain of the receptor. Such mutations generally cause enhanced kinase activity 
and subsequent hyperactivation of downstream signaling cascades culminating in 
increased cell proliferation and survival (Sharma et al., 2007). 
The second member of the ErbB family, ErbB2, possesses the most potent mitogenic power 
as demonstrated by its ability to transform cells even in the absence of a ligand. In fact, 
ErbB2 is the preferred dimerization partner and heterodimers containing this type of 
receptor are characterized by an increased mitogenic signaling. This is best exemplified by 
the ErbB2-ErbB3 heterodimer, which is frequently observed in some of the most 
aggressive tumors and is associated with poor prognosis (Normanno et al., 2006).  
The implication of ErbB2 in tumor formation is best characterized in breast cancer, which 
is the most common type of cancer in women worldwide. Breast cancer occurs at extremely 
high incidence, affecting one in nine women in the western world. ErbB2 overexpression is 
found in approximately 30% of invasive ductal breast carcinomas and correlates with 
tumor metastasis and shorter survival times. The increased invasive potential of cells 
overexpressing ErbB2 is partially due to the ability of the receptor to hyperactivate the 
matrix metalloproteinases MMP-9 and MMP-2, which are involved in degradation of the 
extracellular matrix. In addition, overexpression of ErbB2 confers resistance to apoptotic 
signals, which in turn causes decreased sensitivity of cancer cells to various treatments 
including chemotherapy and hormone therapy (Yu & Hung, 2000).  
Tyrosine Kinase Inhibitors and Their Role in Cancer Therapy 
The central role of aberrant ErbB signaling in the development and progression of tumors 
has made the ErbB network an attractive target for pharmacological intervention. 
Inhibition of ErbB signaling in cancer cells has been intensely pursued over the past two 
decades and, subsequently, led to the development of targeted cancer therapies, in which 
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tyrosine kinase inhibitors are used to specifically block the activity of ErbB receptors. 
Unlike traditional cancer treatments, targeted therapies exhibit a high specificity toward 
malignant cells, which greatly reduces their toxicity to normal cells. Conventional 
chemotherapeutic agents do not discriminate between rapidly dividing normal cells and 
tumor cells which results in multiple toxic side effects. In addition, patients with advanced 
stages of cancer often exhibit only partial and brief improvement after chemotherapy. 
Thus, ErbB targeted therapies provide a novel approach to cancer treatment and have 
already been associated with positive clinical results. Furthermore, targeted therapies can 
be used in combination with conventional chemotherapy and radiation therapy to produce 
additive or synergistic effects and further optimize patients’ responses (Arora & Scholar, 
2005).  
ErbB targeted therapies can be broadly divided into two categories: anti-receptor 
monoclonal antibodies and low-molecular-weight inhibitors of tyrosine kinases. 
Monoclonal antibodies target the extracellular region of the ErbB receptor and prevent 
ligand binding or receptor dimerization. In addition, antibodies induce receptor 
endocytosis leading to ErbB degradation. The resulting inhibition dowregulates 
proliferation and survival pathways initiated by the ErbB receptors. In addition, mAb can 
recruit natural killer cells to tumors, which further inhibits tumor growth. A number of 
monoclonal antibodies targeting the extracellular region of the ErbB receptors have been 
developed (Table 2) (Bacus et al., 2005). 
Table 2: Monoclonal antibodies targeting the ErbB family (Bacus et al., 2005). 
Agent  Target Tumor Type 
Cetuximab ErbB1  Colon, head and neck, lung, pancreas 
Panitumumab ErbB1 Colon, renal 
Matuzumab ErbB1 Head and neck, ovarian, colon, cervix 
h-R3 ErbB1 Head and neck 
Pertuzumab ErbB2  Breast, ovarian, prostate, lung 
Trastuzumab 
(Herceptin) 
ErbB2 Breast 
  
Two of the ErbB monoclonal antibodies, Cetuximab and Herceptin, have been approved by 
the Food and Drug Administration and are currently used in the treatment of lung and 
16 
 
breast cancer, respectively. Clinical data indicate that patients with metastatic breast 
cancer had an improved overall survival when treated with Herceptin and chemotherapy 
as opposed to chemotherapy alone (Slamon et al., 2001). Similarly, clinical trials with 
Cetuximab showed a prolonged overall survival in patients with advanced non-small cell 
lung carcinoma who received a combination of Cetuximab and chemotherapy (Pirker et al., 
2009).  
In contrast to mAb, which bind to the extracellular portion of the ErbBs, low-molecular-
weight inhibitors target the intracellular kinase domain and lead to inhibition of the kinase 
activity and subsequent abrogation of receptor signaling. Small molecule tyrosine kinase 
inhibitors can be further divided into reversible and irreversible inhibitors. Reversible 
small molecule inhibitors bind at the vicinity of the ATP-binding pocket of their target 
kinases, mimicking ATP binding. Thus, these inhibitors compete with the endogenous ATP 
for binding to the kinase domain. Irreversible inhibitors usually react with a cysteine 
residue at the kinase ATP pocket to form a covalent bond. As a result, the inhibitor 
irreversibly blocks ATP binding to the kinase domain and completely abolishes kinase 
activity (Madhusudan & Ganesan, 2004).  
Several small molecule tyrosine kinase inhibitors targeting the ErbB receptors have been 
developed and approved by the FDA for treatment of cancer. Some of the most promising 
and extensively characterized drugs include gefinitib and erlotinib for the treatment of 
non-small-cell lung carcinoma, and lapatinib for the treatment of breast cancer (Table 3).  
Table 3: Small molecule tyrosine kinase inhibitors targeting the ErbB family (Bacus et 
al., 2005). 
Agent  Reversible Target Tumor Type 
Gefitinib Yes ErbB1  Lung 
Erlotinib Yes ErbB1 Lung, pancreas 
Lapatinib Yes ErbB1/2 Breast 
CI-1033 No Pan ErbB Squamous cell carcinoma, skin 
EKB-569 No ErbB1 Colon 
 
Gefitinib and erlotinib are reversible inhibitors of ErbB1 kinase domain and in vitro studies 
with cancer cell lines demonstrated that dose-depended inhibition of ErbB1 
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autophosphorylation was associated with decreased cell growth. Clinical trials 
subsequently showed that gefitinib improve survival rates only in a subgroup of patients 
who have specific activating ErbB1 mutations. These mutations are associated with 
enhanced receptor signaling and conferred increased receptor susceptibility to gefinitib. 
On the other hand, erlotinib has been demonstrated to significantly improve survival rates 
of paients overexpressing wild type ErbB1 (Laack et al., 2010).  
Lapatinib is a dual specificity inhibitor and was approved by the FDA for the treatment of 
advanced or metastatic breast cancer in combination with other therapies. Results from 
clinical studies indicate that the drug is beneficial to patients and in combination with 
chemotherapy can increase time to disease progression and progression-free survival rates 
(Paul et al., 2008).  
As a class of molecularly targeted therapies, small molecule tyrosine kinase inhibitors have 
made a substantial contribution towards improvements in cancer therapies. They are 
usually well tolerated, with more manageable toxicity profiles as compared to conventional 
cytotoxic chemotherapies. In addition, small molecule tyrosine kinase inhibitors represent 
a novel approach for the treatment of patients with advanced stages of cancer and have 
improved the quality of life of patients with poor prognosis. Unfortunately, patients treated 
with mAb or small molecule tyrosine kinase inhibitors eventually develop drug resistance. 
Selective pressure in the rapidly dividing tumor cells leads to emergence of drug-resistant 
ErbB receptor variants with kinase domain mutations that abrogate drug binding to the 
ATP-pocket. Therefore, there is a need to develop novel inhibitors that circumvent the 
resistance problem. One approach is to design drugs that can tolerate a range of amino 
acids at the gatekeeper position of the kinase catalytic pocket. The gatekeeper residue 
determines the accessibility of a hydrophobic pocket located next to the ATP-binding site. 
Hydrophobic interactions between the receptor and the inhibitor in the hydrophobic 
pocket are essential for the inhibitor binding affinity. A second strategy to overcome drug 
resistance is to target the kinase domain with inhibitors binding at alternative sites (Zhang 
et al., 2009).  
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The need to discover novel tyrosine kinase inhibitors comes with the challenge to evaluate 
drug potency and selectivity at the organismal level. In vitro studies with cell culture 
demonstrate that different cancer cell lines often exhibit markedly different responses to 
the same inhibitor. Therefore, new approaches to evaluate a given inhibitor in the context 
of a living organism may provide a more accurate assessment of the drug potency and 
efficacy (Zhang et al., 2009).  
 
Drosophila as a Model System for Drug Validation 
Despite rapid advances in elucidating the molecular basis of cancer, oncology drug 
discovery remains a challenging undertaking. Anti-cancer drug candidates have 
significantly lower rates in clinical development compared to compounds in other areas 
such as cardiovascular and infectious diseases (Kamb et al., 2006). A crucial step in the 
process of developing a therapeutic agent is early validation of the efficacy of drug 
candidates. Cultured cancer cell lines are widely utilized in the early stages of drug 
discovery to screen libraries of compounds for an ability to produce a desired physiological 
outcome. Although conventional cell culture assays are convenient to use in a high-
throughput screen, they have several major limitations. Cell culture systems cannot 
recapitulate many aspects of the in vivo cell microenvironment and, therefore, fail to 
account for many of the complex cell and tissue interactions that occur at the level of an 
intact organism. As a result, many drug candidates selected on the basis of cell culture 
assays fail to exhibit the necessary level of efficacy in subsequent validation stages in 
animal models. To overcome these limitations, novel drug validation approaches need to be 
incorporated into the early stages of the drug discovery process (Bell et al., 2009). 
The sequencing of human and other eukaryotic genomes has revealed a striking 
conservation of biochemical modules that control fundamental cellular processes such as 
proliferation, differentiation and migration. It is, therefore, feasible to consider utilizing 
invertebrate model organisms as a drug discovery and validation tool to increase the rate 
of discovery of higher quality leads.  
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The fruit fly Drosophila melanogaster possesses several compelling features that make it a 
particularly attractive model organism to use for in vivo drug validation. Drosophila has a 
short generation time and large populations can be grown in a laboratory setting at an 
extremely low cost, which greatly enhances the efficiency of the experimental studies. This 
is coupled with sophisticated tools for genetic manipulation, as well as a complete genome 
sequence (Matthews & Kopczynski, 2001). In fact, comparative genome analyses indicate 
that 61% of the disease genes in humans have been conserved in flies. Moreover, many 
vital developmental pathways and cascades are also conserved from flies to humans. Thus, 
it is possible to use Drosophila as a simple organism to dissect the molecular basis of 
complex diseases such as cancer. For instance, a study of the oncogene ras in flies led to the 
identification of novel genes that modulate the same signaling network in humans. In 
addition, the guanine nucleotide exchange factor SOS (son-of-sevenless), which promotes 
exchange of GDP to GTP on Ras and activates it was first identified in Drosophila (Muda & 
McKenna, 2004). 
Perhaps one of the most compelling features of Drosophila as a model system is the ability 
to target gene expression in a temporal and spatial manner using the driver-responder 
GAL4/UAS system. In this binary system, a gene of interest is cloned behind a UAS 
(upstream activating sequence) element, which contains five GAL4 binding sites. In the 
absence of the transcription factor GAL4, the gene of interest (responder) is 
transcriptionally silent. When flies containing the responder are crossed to lines expressing 
GAL4 in a tissue-specific manner, the resulting progeny expresses the gene of interest as a 
result of GAL4 binding to the UAS. This elegant tool for genetic manipulation has been 
invaluable for investigating gene function in vivo (Duffy, 2002).  
Due to its small size, short generation time and low cost of culture, Drosophila can also be 
used in high-throughput screens of libraries of compounds. In fact, whole animal assays can 
be set up on standard microtiter plates (96 wells) to identify or validate novel anti-cancer 
drugs or elucidate the mode of action of a given compound. Such high-throughput in vivo 
pharmacological screens have low costs and can increase the efficiency of the drug 
discovery and validation process (Muda & McKenna, 2004).  
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The high degree of conservation of the ErbB signaling module between Drosophila and 
humans makes it feasible to consider flies as potential model organism for in vivo 
pharmacological assays related to the ErbB receptors.  
Epidermal Growth Factor Receptor Signaling in Drosophila Oogenesis  
In Drosophila the epidermal growth factor receptor (DER) specifies cell fates and has 
several important roles throughout development.  During oogenesis the receptor is 
required for establishment of the dorsoventral and anterior-posterior axes of both the 
eggshell and the embryo (Shilo, 2003).  
Drosophila female flies have two ovaries containing approximately 18 ovarioles. A 
specialized structure at the tip of each ovariole, the germarium, gives rise to egg chambers 
which mature into eggs as they pass down the ovariole. Each egg chamber consists of a 
germline-derived oocyte and nurse cells enclosed in a monolayer of follicular epithelium 
(Fig. 6) (Cavaliere et al., 2008). In the early stages of oogenesis DER signaling in the 
posterior follicle cells establishes the anterior-posterior axis of the egg chamber. In the 
later stages of oogenesis, DER signaling is confined to a subpopulation of dorsal-anterior 
follicle cells, where the receptor specifies the dorsal fate of these cells and establishes the 
dorsoventral polarity of the eggshell. DER signaling in the follicle cells is activated by a 
TGF-α-like ligand, Gurken, which is expressed on the surface of the oocyte and only 
proximal to the nucleus. During oogenesis, the nucleus moves from its initial position at the 
posterior end of the oocyte to the dorsal anterior site, thus causing a re-localization of 
Gurken expression. DER signaling also specifies the differentiation and positioning of the 
two dorsal-anterior appendages in the embryo. Inhibition of DER signaling causes 
ventralization of the chorion and loss of the two dorsal appendages. On the other hand, 
overexpression of the receptor leads to dorsalization of the chorion (i.e. ectopic expression 
of dorsal appendages) (Wasserman & Freeman, 1998) .  
 
Figure 6: Stages of Drosophila Oogenesis. (University of Newfoundland, 2010)  
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Materials and Methods 
Generating ErbB Expression Clones 
The Gateway Cloning System was used to generate ErbB expression clones. The Gateway 
Cloning Technology is a universal cloning system in which DNA fragments can be cloned 
into a variety of vectors without the use of restriction endonucleases. Instead, the Gateway 
Technology takes advantage of the lambda phage recombination system, which is used to 
transfer DNA fragments into vectors containing specific recombination sites called att sites.  
Two types of in vitro reactions, BP and LR, are mediated by a mix of clonase enzymes and 
transfer a DNA sequence of interest first into an entry vector and then into a final 
expression vector. The BP reaction is a recombination between a gene of interest flanked 
by attB1 and attB2 sites, and a donor vector containing a ccdB gene flanked by attP1 and 
attP2 sites. In the resulting entry clone, the DNA sequence of interest is flanked by attL 
sites. The LR reaction is then a recombination between the attL sites of the donor vector 
and the attR sites of the destination vector. The resulting expression clone contains the 
gene of interest flanked by attB sites and can be used to generate transgenics.  
Selection of positive clones is achieved by the presence of a kanamycin and ampicillin 
resistance genes in the Gateway vectors. In addition, empty entry and destination vectors 
contain a ccdB gene, which is toxic to E. coli and prevents growth on medium. Thus, only 
clones containing the gene of interest are recovered, which greatly increases the efficiency 
of the cloning process (Fig. 7) (Invitrogen).  
Figure 7: Gateway Recombination Cloning Technology (Adapted from Ivitrogen) 
ErbB2 entry clones previously generated in the Duffy Lab were used in an LR reaction with 
a pUAST GFP destination vector to create an expression clone: 7µL pENTR ErbB2, 1µL of 
150ng/µL pUAST GFP and 2µL LR Clonase mix were incubated at 250C overnight. 5µL of 
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the LR reaction were transformed into DH5α Max Cloning Efficiency cells and plated on LB 
agar plates containing 50µg/mL ampicillin. Colonies were grown overnight in small liquid 
LB cultures containing ampicillin and were then miniprepped using Qiagen’s Qiaprep Spin 
Miniprep Kit. Positive clones were verified by restriction enzyme digestion and 
midiprepped with Qiagen’s Plasmid Midi Kit. The DNA was then sent to Yale’s DNA Analysis 
Facility for sequencing and the resulting chromatograms were analyzed using the 
Sequencher software.  
Generation and Mapping of ErbB1 and ErbB2 Transgenic Drosophila  
The midiprepped DNA for pUAST-ErbB2-GFP expression clone and maxiprepped DNA for 
pUAST-ErbB1-GFP (previously generated in the Duffy Lab) was sent to Genetic Services, 
Inc. (Cambridge, MA) for injection into w1118 (wild type) Drosophila embryos. The resulting 
surviving larvae were returned to the lab for transgenic screening and mapping. Surviving 
flies (generation G0) were single-pair mated to 3-4 w1118 males or virgin females depending 
on the sex of the putative transgenic. w1118  flies have no eye pigmentation but the 
expression constructs injected into embryos contained the white gene responsible for eye 
color production. Therefore, eye-colored progeny from the previous mating indicated 
presence of the transgene. These transgenics (generation F1) were collected and mated to 
flies of the genotypes [w-; Sp/CyO (chromosome II); +/+] and [w-; +/+; Ly/TM3 Sb 
(chromosome III), for mapping purposes. From these matings, heterozygous progeny 
containing both eye color and the Balancer chromosome marker (CyO or TM3 Sb) were 
collected and outcrossed back to w1118 flies to determine the segregation pattern of the 
transgene versus the marker. Figure 8 and 9 depict the mapping scheme of transgenic 
strains containing an insert in the second and third chromosomes, respectively. 
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Figure 8: Transgene Mapping Outline (Chromosome II insertion) 
A consistent segregation of the transgene away from the Balancer chromosome marker 
indicates transgene insertion into that respective chromosome. For instance, if the 
transgene always segregates away from the CyO marker, the construct must have inserted 
into the second chromosome.  
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Figure 9: Transgene Mapping Outline (Chromosome III insertion) 
Once mapped, stable stocks of the transgenic strains were generated by first mating one 
transgenic male of the genotype [pUAST-ErbB-GFP/+] to 4-5 males of the respective 
balancing strain [Sp/CyO for chromosome II insertion or Ly/TM3 Sb for chromosome III 
insertion]. From this cross, female and male progeny of the genotype [pUAST-ErbB-
GFP/CyO or pUAST-ErbB-GFP/TM3 Sb] were mated to each other to generate the final 
stable transgenic stock.  
For transgene insertions into the X chromosome (chromosome I), transgenic females were 
mated to FM6, y w B males. From this mating, female progeny of the genotype [pUAST-
ErbB-GFP/ FM6, y w B] were crossed back to FM6, y w B males to generate the final stable 
transgenic stock.  
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Gain-of-function Studies with the Gal4/UAS System 
The Gal4/UAS system is used for targeting gene expression in a temporal and spatial 
manner by mating a driver strain (GAL4) to a responder strain (UAS). In this binary system, 
a gene of interest is cloned behind a UAS (upstream activating sequence) element, which 
contains five GAL4 binding sites. In the absence of the transcription factor GAL4, the gene 
of interest (responder) is transcriptionally silent. When flies containing the responder are 
crossed to lines expressing GAL4 in a tissue-specific manner, the resulting progeny 
expresses the gene of interest as a result of GAL4 binding to the UAS. Expression levels of 
the responder gene are also dependent on the temperature at which the cross is carried 
out. Higher temperature corresponds to higher expression levels (Duffy, 2002). 
The CY2 GAL4 driver was used in these studies to misexpress ErbB1, ErbB2 and DER 
during oogenesis(Fig.10) Female CY2 GAL4 driver flies were crosses to 5-6 [pUAST-
ErbB1/ErbB2/DER-GFP] males. For strains containing transgene insertion in the X 
chromosome, male CY2 GAL4 driver flies were mated to responder (UAS) females. All 
crosses were set up and maintained at 200C 
 
Figre 10: ErbB Missexpression during Oogenesis 
Adult Ovary Dissection and Mounting 
Adult female ovaries were dissected in PBT, fixed in 3.7% formaldehyde for 15 min and 
mounted on a slide in 50% glycerol in PBP. GFP localization in stage 10 egg chambers was 
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examined using a fluorescent Zeiss Imager.Z microscope with Apotome at 20X. Images 
were captured using a Zeiss Axiocam and were processed with Zeiss’s Axiovision software. 
Chorion Preps 
Female and male flies overexpressing ErbB1, ErbB2 or DER during oogenesis were placed 
on apple juice egg lay plates covered with a small beaker. The flies were kept at 250C 
overnight. On the following day, the original plates were replaced with new ones and 
chorions were collected and mounted on a microscope slide in Lacto-Hoyer’s (1:1) solution. 
The slide was placed on a hotplate overnight at 650C. Chorions were examined for a 
dorsalization phenotype usinhg dark field microscopy on a Zeiss Imager.Z1 (10X). 
Drug Screening Assay Design 
The drug treatment experiments were set up in an 80-well eppie rack. Each well contained 
1mL apple juice agar prepared by the following recipe: 3.3g agar were added to 60mL of 
dH2O and 90mL apple juice in a 1L plastic beaker. The mixture was microwaved for 1.5 min 
after which 5g sugar were added. 1mL of the mixture was poured into each well and left to 
solidify.  
The small molecule tyrosine kinase inhibitors CL-387,785 and PD 168393 ordered from 
Calbiochem were dissolved in 200µL DMSO to yield a concentration of approximately 
13.5mM. Apple juice and dH2O mixed in a 1:1 ratio were used to dilute the CL-387,785 (CL) 
and PD 168393 (PD) stocks to 1:100. 10µL of each inhibitor dilution were pipetted on top 
the solidified apple juice agar in the wells. Female flies overexpressing ErbB1 or ErbB2 
during oogenesis were then placed in the wells together with two male flies. The wells 
were covered with scotch tape with small holes to allow in air. The racks were kept at 250C. 
After 24 hours the flies were transferred to new racks containing freshly poured apple juice 
agar and the same amount and concentration of inhibitor solution. The overall drug 
screening set up is outlined in Fig. 11.  
The chorion phenotype was scored every 24 hours over the course of 7 days. For each 
transgenic strain, the inhibitor treatment was done in triplets and also included an 
untreated control.  
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Figure 11: Drug Screening Assay Set Up 
 
 
 
 
 
 
 
Results 
Transgenic Drosophila strains containing the human ErbB1 or ErbB2 receptors were 
successfully generated and mapped. To characterize receptor localization and activity, 
ErbB1 and ErbB2 were missexpressed during Drosophila oogenesis. These functional tests 
demonstrated that both receptors have activity and are properly localized. Furthermore, in 
some transgenic strains tyrosine kinase inhibitor treatments reversed the phenotype 
caused by missesxpression of the human receptors.  
Transgenic Drosophila Strains Mapping  
Constructs pUAST-ErbB1-GFP and pUAST-ErbB2-GFP were sent to Genetic Services, Inc. for 
injection into embryos. Surviving larvae were returned to the lab and the resulting adults 
were single-pair mated to w1118 flies of the opposite sex. The transgenic progeny were 
selected based on eye color and were again single-pair mated to w1118 flies to map the 
position of the transgene as outlined in Materials and Methods. For each construct, 13 
transgenic strains were obtained and mapped (Table 4&5).  
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Table 4: pUAST-ErbB1-GFP Mapping Results 
Strain Color Chromosome 
SAA3M-1F Dark Orange 3 
SAA4M-1M  Orange 3  
SAA3F-1M Dark Orange 2 
SAA6F-1M Orange 1 
SAA7F-1M  Red 3  
SAA9M-1M Orange 3 
SAA11F-1M  Red 2  
SAA15M-1M Dark Orange 2 
SAA17M-1F Yellow with 
patches of red 
2 
SAB2M-1M Orange 3 
SAB8M-1M  Dark Orange 3  
SAB9F-1M Red 2 
SAB10F-1M  Red 3  
 
 
 
 
 
 
Table 5: pUAST-ErbB2-GFP Mapping Results 
Strain Color Chromosome 
ARA8M-1M Orange 2 
ARA13F-1M Orange 1 
ARA15F-1M  Dark Orange 2  
ARA16F-1M Dark Orange 2 
ARA24F-1M Dark Orange 3 
ARA26F-1M Dark Orange 3 
ARA28F-1M Orange 3 
ARA36M-1M Dark Orange 3 
ARA37M-1M Orange 3 
ARA38M-1M Dark Orange 3 
ARA43M-1M Orange 2 
ARA51M-1M Dark Orange 3 
ARA53M-1M Orange 2 
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Functional Analysis of Human ErbB Receptors in Drosophila 
To characterize the localization and activity of the human receptors in Drosophila, ErbB1 
and ErbB2 were missexpressed by crossing transgenic strains to CY2 GAL4 flies as outlined 
in Materials and Methods. In the larval stages, CY2 GAL4 causes expression in the salivary 
glands. During oogenesis CY2 drives protein expression in the follicle cells surrounding egg 
chambers. Localized DER signaling specifies the dorsal fates of a subpopulation of follicle 
cells and establishes the dorsoventral axis of the embryo. Previous studies have shown that 
misexpression of DER during oogenesis results in dorsalization of the chorion. This 
phenotype is also characterized by fusion and ectopic expression of the dorsal respiratory 
appendages of the embryo (Queenan et al., 1997). Thus, the dorsalized chorion phenotype 
was used in these functional studies as a measure of receptor activity.  
Since preliminary functional analysis indicated that missexpression of the transgenes 
causes lethality at room temperature, the cross between the CY2 GAL4 driver and the 
transgenic responder strain was set up and maintained at 200C. The developing larvae and 
pupae were examined for GFP expression in the salivary glands. The F1 progeny were then 
collected and transferred to 250C to examine chorions for a dorsalization phenotype. GFP 
expression in the larval and pupal salivary glands was indicative of full translation of the 
ErbB1 and ErbB2 receptors, while the dorsalized chorion phenotype indicated receptor 
activity.  The results are summarized in tables 6 and 7.  
Five ErbB1 strains (SAA4M-1M, SAA7F-1M, SAA11F-1M, SAB8M-1M, SAB10F-1M)     
exhibited strong GFP expression in larval and pupal stages and correlated with a consistent 
dorsalized chorion phenotype at 250C. Except for SAB8M-1M, these strains had relatively 
high viability (Table 6).  
Of the 13 ErbB2 transgenic strains, 5 were lethal even at 200C. Only one strain, ARA15F-1M, 
exhibited the dorsalized chorion phenotype at 250C (Table 7).  
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Table 6: CY2 Gal4 Misexpression of pUAST-ErbB1-GFP. 
Strain GFP in Salivary Glands (200C) Chorion 
Phenotype (250C) Larva Pupa 
SAA3M-1F + + WT 
SAA4M-1M  +  ++  Dorsalized  
SAA3F-1M + + WT 
SAA6F-1M + + WT+Dorsalized 
SAA7F-1M  +++  +++  Dorsalized  
SAA9M-1M - - WT 
SAA11F-1M  +++  +++  Dorsolized  
SAA15M-1M +++ +++ WT+Dorsalized 
SAA17M-1F +++ +++ WT+Dorsalized 
SAB2M-1M + + WT 
SAB8M-1M  +++  +++  Dorsalized  
SAB9F-1M + + WT 
SAB10F-1M  +++  +++  Dorsalized  
 
 
Table 7: Cy2 Gal4 Misexpression of pUAST-ErbB2-GFP. 
Strain GFP in Salivary Glands (200C) Chorion 
Phenotype (250C) Larva Pupa 
ARA8M-1M - - WT  
ARA13F-1M + lethal  
ARA15F-1M  +  +  Dorsalized  
ARA16F-1M - - WT 
ARA24F-1M + lethal  
ARA26F-1M - - WT 
ARA28F-1M - +  WT 
ARA36M-1M lethal   
ARA37M-1M +++ +++  
only in prepupa 
WT 
ARA38M-1M lethal   
ARA43M-1M +++ lethal  
ARA51M-1M + ++ WT 
ARA53M-1M + ++ WT 
 
To characterize the pattern of localization of the human receptors, ovaries from female flies 
overexpressing ErbB1 or ErbB2 were dissected and the follicular epithelium of stage 10 
egg chambers was examined for GFP expression. As shown in Fig. 12A, the follicle cells 
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form a monolayer that surrounds the egg chamber. To determine the overall level of 
receptor activity, chorions were collected and examined for the degree of dorsalization. As 
shown in Fig. 12B, a wild type chorion has a well-defined dorsal-ventral axis with two 
appendages on the dorsal side. A dorsalized chorion is characterized by ectopic expression 
of dorsal appendages.   
 
Figure 12: A, Stage 10 Drosophila egg chamber; B, Wild type Drosophila chorion. 
 
The Drosophila EGFR receptor (DER) was also missexpressed during oogenesis with the 
CY2 GAL4 driver. DER was used as a control and was compared to human receptors. ErbB1 
and ErbB2 were expressed within the follicle cells of stage 10 egg chambers and their 
expression was properly localized to the cell membrane (Fig. 13A). The levels of expression 
were relatively similar across the ErbB1 and ErbB2 transgenic strains. However, the DER 
strain exhibited a lower expression level and a different localization pattern. Although the 
receptor was also properly localized to the cell membrane, not all follicle cells expressed 
the protein at the same level (Fig. 13A). It is possible that the lower expression levels of 
DER were due to receptor endocytosis and subsequent lysosomal degradation through 
recruitment of the Cbl ubiquitin ligase. The Drosophila Cbl may not recognize the 
phosphotyrosine residues at the C-terminal tail of the human receptors as binding sites. As 
a result, once endocytosed, ErbB1 and ErbB2 would not be ubiquitinated by Cbl. Therefore, 
rather than degraded, the human receptors are probably recycled back to the cell 
membrane.  
 
Misexpression of both the human receptors and DER during oogenesis resulted in a 
dorsalized chorion phenotype (Fig. 13B), suggesting that ErbB1 and ErbB2 were active.  
Chorions from strains overexpressing DER had a less severe and consistent dorsalized 
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phenotype as compared to the transgenic ErbB1 and ErbB2 strains.  In particular, ErbB1 
strain SAA7F-1M, and ErbB2 strain ARA15F-1M, exhibited a severe dorsalized phenotype 
as demonstrated by a characteristic peanut chorion shape (Fig. 13B). 
 
Figure 13: A, Receptor expression levels and localization pattern; B, chorion 
phenotypes induces by receptor misexpression 
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Tyrosine Kinase Inhibitor Screening Assay 
The transgenic ErbB Drosophila strains that exhibited proper receptor localization and 
receptor activity demonstrated by a dorsalized chorion phenotype were used in a drug 
screening assay as described in Materials and Methods. During oogenesis DER specifies the 
dorsal fates of the egg chamber follicle cells and, thus, establishes the dorsoventral axis of 
the developing egg chamber, chorion and embryo. DER signaling also specifies the 
differentiation and positioning of the two dorsal-anterior appendages in the chorion. 
Inhibition of DER signaling causes ventralization of the chorion and loss of the two dorsal 
appendages. On the other hand, overexpression of the receptor leads to chorion 
dorsalization and ectopic expression of dorsal appendages (Wasserman & Freeman, 1998).  
Previous work in the Duffy Lab by C. Leduc demonstrated that feeding transgenic flies 
overexpressing ErbB1 with small molecule tyrosine kinase inhibitors resulted in reversion 
of the dorsalized chorion phenotype to a wild type phenotype. This provides a simple way 
to assess the activity and potency of novel small molecule tyrosine kinase inhibitors and 
can potentially be adopted as a whole animal in vivo approach to identify or validate novel 
cancer therapeutics.  
Two known tyrosine kinase inhibitors, CL-387,783 and PD 163393 (Fig. 14), were tested 
for an ability to suppress the dorsalized chorion phenotype in the transgenic strains 
overexpressing ErbB1 and ErbB2. CL-387,783 (N-[4-[(3-Bromophenyl)amino]-6-
quinazolinyl]-2-butynamide) and PD 163393 (4-[(3-Bromophenyl)amino]-6-
acrylamidoquinazoline) belong to a quinazoline class of irreversible inhibitors. 
Experimental data demonstrate that the two TKI inhibit ErbB signaling by covalently 
binding to a cysteine residue at position 773 in the ATP pocket of the receptor, thus 
preventing subsequent ATP binding (Discafani & Carroll, 1999; Fry et al., 1998). CL-
387,783 was shown to be specific to ErbB1 (Discafani & Carroll, 1999), while experimental 
data suggest that PD 163393 can bind and inhibit both ErbB1 and ErbB2 (Fry et al., 1998).  
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Figure 14: Structure of CL-387,783 (A) and PD 163393 (B) (Taken from 
EMD/Calbiochem website: http://www.emdbiosciences.com/product/233100 and 
http://www.emdchemicals.com/life-science-research/products/EMD_BIO-
513033/p_uuid) 
Four ErbB1 (SAA4M-1M, SAA7F-1M, SAA11F-1M and SAB10F-1M) and one ErbB2 
(ARA15F-1M) transgenic strains were used in the drug screening assay. The effect of the 
inhibitors on wild type flies was also tested.  
Functional analysis of the human receptors revealed that two of the ErbB1 transgenic 
strains, SAA4M-1M and SAA7F-1M, exhibited a strong and very consistent dorsalized 
chorion phenotype when the receptor was overexpressed during oogenesis. Treatment of 
these strains with CL-387,783 increased the appearance of wild type chorions from 0% 
(untreated strains) to 14% in SAA4M-1M and 5% in SAA7F-1M (Fig. 15). In addition, 
treated flies from the strain SAA7F-1M appeared to lay larger amounts of chorions than the 
untreated flies. Strains SAA11F-1M and SAB10F-1M also exhibited strong chorion 
dorsalization but the phenotype was less consistent and the flies were laying a small 
number of wild type chorions as well. Treatment with the CL-387,783 inhibitor increased 
the appearance of wild chorions from 16% to 33% in SAA11F-1M and from 8% to 32% in 
SAB10F-1M. No effect was observed on the wild type strain since both treated and 
untreated flies laid only wild type chorions (Fig. 15).  Although CL-387,783 is not specific 
for ErbB2, the transgenic line expressing this receptor was still treated with the inhibitor. 
No effect on the ErbB2 strain (ARA15F-1M) was observed, since both the treated and 
untreated females laid severely dorsalized eggs (Data not shown). 
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Figure 15: Effect of CL-387,783 (1:100 dilution) treatment on ErbB1 and wild type 
Drosophila strains (n=total number of chorions) 
 
 
Treatment of the ErbB transgenic strains, SAA4M-1M and SAA7F-1M, with PD 163393 
appeared to have no effect on the dorsalized chorion phenotype. By contrast, this 
compound increased the appearance of wild type chorions from 7.4% (untreated flies) to 
22.33% in the SAA11F-1M strain and from 2.8% (untreated flies) to 18.8% in treated flies 
in strain SAB10F-1M. Similar to results obtained with CL-387,783, PD 163393 did not affect 
the chorion phenotype in the wild type strain (Fig. 16). PD 163393 has specificity for the 
ErbB2 receptor, but both treated and untreated flies from the ErbB2 transgenic strain laid 
eggs with severely dorsalized phenotype (Data not shown). 
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Figure 16: Effect of PD 163393 (1:100 dilution) treatment on ErbB1 and wild type 
Drosophila strains (n=total number of chorions) 
 
Discussion 
Aberrant signaling by the ErbB receptor family is a common feature of multiple types of 
human malignancies. Designing novel therapeutics to specifically target these receptors 
may provide better treatments and optimize patients’ outcome. Since early validation of 
drug efficacy is a crucial step in the drug discovery process, a whole animal, in vivo 
screening approach may be a valuable tool to increase the rate of identification of higher 
quality leads. Transgenic Drosophila expressing properly localized and active ErbB 
receptors can potentially be utilized as a model system to screen for novel therapeutics for 
ErbB based cancers.  
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In the current study, thirteen transgenic Drosophila strains containing the human ErbB1 or 
ErbB2 genes were successfully generated and the chromosome position of each insert was 
mapped (Table 4&5). Subsequent misexpression experiments with the CY2 GAL4 driver 
indicated a proper localization of the two receptors. Since the ErbB receptors are 
transmembrane proteins they should be localized to the cell membrane. Because CY2 GAL4 
drives protein expression during oogenesis, stage 10 egg chambers were examined for 
receptor expression and localization pattern. GFP expression in egg chambers from ErbB1 
or ErbB2 transgenic strains was confined to the follicle cells and appeared to be localized to 
the cell membrane (Fig.12). This suggests that the GFP-tag does not interfere with the 
proper receptor expression and transport to the cell membrane.  
The receptor expression levels were relatively the same across the ErbB1 and ErbB2 
transgenics, but the strain containing the fly EGFR receptor (DER) had significantly lower 
GFP expression, although it was still membrane localized. In addition, only distinct patches 
of follicle cells appeared to strongly express GFP. These data suggest that DER is probably 
endocytosed and targeted for degradation through recruitment of the ubiquiting ligase Cbl. 
Drosophila has a single Cbl protein, D-Cbl, which is homologous to the mammalian c-Cbl. 
The human Cbl proteins can interact with the ErbB receptors by directly associating their 
PTB-binding domains with distinct C-tail phosphotyrosine residues. In addition, Cbl can 
bind to and utilize Grb2 as an adaptor protein to associate with the active receptors (Sorkin 
& Goh, 2009). Although Drosophila has a homolog of the human adaptor Grb2, called Drk, 
D-Cbl cannot bind to that adaptor protein. This is due to the fact that D-Cbl cannot interact 
with SH3-domain containing protein since it is C-terminally truncated. However, D-Cbl is 
still able to associate with activated DER, possibly through direct binding to distinct 
receptor phosphotyrosine residues. If these binding sites are not conserved from flies to 
humans, this may suggest that the human receptors in transgenic Drosophila cannot be 
ubiquitinated by D-Cbl and, therefore, may be able to escape the lysosomal degradation 
pathway following endocytosis (Hime et al., 1997).  
Based on previous work in the Duffy Lab by C. Leduc, conserved phosphotyrosine residue 
binding sites were identified across the human ErbB receptors and the fly receptor. It was 
determined that both ErbB1 and ErbB2 contain two binding sites for the adaptor protein 
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Grb2 and one for the Shc adaptor (Fig. 17). Thus, it was hypothesized that the human 
ErbB1 and ErbB2 receptors would be able to activate downstream signaling pathways in 
Drosophila. Consistent with this hypothesis, functional analysis of ErbB1 and ErbB2 in 
transgenic Drosophila strains indicate that both receptors have activity.  
 
Figure 17: Conserved tyrosine residues at the C-terminal tails of the ErbB and DER 
receptor (Taken from: C. Leduc, 2007) 
Misexpression of ErbB1 and ErbB2 during oogenesis resulted in a dorsalized chorion 
phenotype as shown in Fig. 13. The ability of the human receptors to produce the same 
phenotype caused by overexpression of the fly receptor indicates that ErbB1 and ErbB2 
must be capable of associating with Drosophila adaptor proteins and activating the MAPK 
signaling cascade.  
Since ErbB1 and ErbB2 are properly localized to the cell membrane and have activity in 
flies, it seems feasible to consider using transgenic Drosophila in an in vivo assay to identify 
novel therapeutic agents for ErbB-based cancers. Towards this goal, a drug screening assay 
was set up, in which two known small molecule tyrosine kinase inhibitors, CL-387,783 and 
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PD 163393, were tested for an ability to suppress signaling by ErbB1 and ErbB2 in 
transgenic flies overexpressing the receptors during oogenesis. Since a dorsalized chorion 
phenotype is indicative of receptor activity, reversion of this phenotype to wild type would 
be a sign of ErbB signaling inhibition. CL-387,783 treatment increased the appearance of 
wild type chorions in all four of the ErbB1 strains that were tested. After treatment, higher 
percent wild type chorions was observed in strains SAA11F and SAB10F as compared to 
the other two strains. Although SAA11F and SAB10F exhibit a strong dorsalized phenotype, 
it is less consistent as demonstrated by the presence of small amounts of wild type eggs 
even in the untreated strains.  
Treatment with inhibitor PD 163393 increased the appearance of wild type chorionsin in 
both SAA11F and SAB10F, but had no effect on the SAA4M-1M and SAA7F-1M strains. The 
ErbB1 strain SAA7F-1M exhibited a severe dorsalized phenotype, which was also very 
consistent. A more robust reversion of this severely dorsalized chorion phenotype to wild 
type may require higher inhibitor concentrations and longer treatment periods. The ErbB2 
transgenic strain ARA15F had the most severe chorion phenotype, as demonstrated by a 
characteristic peanut shape. Again, the severity of the phenotype may explain why PD 
163393 had no effect on this strain, although this inhibitor has been shown to have 
specificity to the ErbB2 receptor as well.   
The two small molecule tyrosine kinase inhibitors were also tested on wild type Drosophila 
strains. If the compounds were able to inhibit the basal signaling levels of the endogenous 
DER receptor, then the treated wild type flies would be expected to lay ventralized eggs. 
However, both the treated and untreated wild type strains laid only wild type eggs. This 
suggests that CL-387,783 and PD 163393 were not inhibiting the endogenous DER receptor 
and that the increased appearance of wild type eggs in the ErbB1 strains was due to 
specific inhibition of this receptor. Together, these data indicate that it is feasible to utilize 
transgenic Drosophila to screen for therapeutics that specifically block ErbB signaling.  
The ErbB1 and ErbB2 transgenic Drosophila strains can also be utilized in high-throughput 
screens of libraries of compounds. However, it is important to first optimize the current 
assay conditions. One particular problem in this screening assay is the drug delivery 
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approach. A small amount of inhibitor solution was pipetted on top on the solidified apple 
juice agar in each well. However, using this delivery method, whether the flies are actually 
eating the food containing the inhibitor and relative dosing cannot be easily assessed. 
Consequently, it becomes difficult to assess if absence of an effect is really due to poor drug 
efficacy or dosing.  
One solution to the delivery approach would be to mix the apple juice agar with food 
coloring. A better alternative, however, would include a tool that would allow precise 
measurement of ingestion. One such tool, the Capillary Feeder (CAFE) assay, described by 
William W. Ja et al., uses graduated glass microcapillaries to deliver liquid food to flies kept 
in small chambers. This method allows for precise quantification of actual ingestion in 
individual Drosphila flies and is, therefore, an excellent tool to monitor oral drug delivery. 
The Capillary Feeder also circumvents the need to add supportive materials into the food 
such as coloring or agar (Ja et al., 2007). Combining the Capillary Feeder with the drug 
screening assay described in the current study can potentially produce a useful tool to 
identify or validate novel therapeutics targeting the ErbB receptor family. Since drug intake 
with the CAFE assay can be continuously monitored and quantified, a presence or absence 
of a drug effect can be more strongly correlated to the efficacy of the given compound.  
The positive results obtained with the in vivo tyrosine kinase inhibitors screen 
demonstrated the potential of transgenic Drosophila as a model organism for drug 
discovery. The incorporation of transgenic Drosophila drug screens with sophisticated drug 
delivery tools into the early stages of the drug discovery process may provide a potential 
means to enhance the efficiency of early drug validation, and thus help to streamline the 
drug discovery process. In addition, Drosophila represents a simple in vivo model system to 
study the complex interaction of the human ErbB receptors. Strains expressing 
combinations of human ErbB receptor could be useful models to study specific receptor 
interactions. For instance, the ErbB2-ErbB3 heterodimer is the most mitogenic receptor 
complex and is implicated in a number of cancers. Studying the ErbB family in a simple 
model system can help gain insight into signaling mechanisms and, subsequently, provide a 
rationale for the development of novel targeted cancer therapies. 
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